Comparative Pharmacology
Head-to-head clinical analysis: DEXAIR versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAIR versus KENALOG IN ORABASE.
DEXAIR vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEXAIR (dexamethasone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., cytokines, prostaglandins). It also inhibits leukocyte infiltration and reduces capillary permeability.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Inhalation: 2 inhalations (80 mcg each) twice daily, maximum 640 mcg/day.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Terminal elimination half-life: 3.0-4.5 hours in adults with normal renal function; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 2-5 hours following mucosal application.
Renal (urinary): ~65-75% as unchanged drug and metabolites; biliary/fecal: ~20-30% as metabolites; less than 10% unchanged in bile.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid